Lexicon Pharmaceuticals

4M Therapeutics Strengthens Executive Leadership Team with Appointment of Kimberly Lee, D.O. as Chief Business Officer

Retrieved on: 
Monday, March 4, 2024
Biotechnology, Neurology, Mental Health, Health, Pharmaceutical, ThinkEquity, Acquisition, Corporate communication, Research, Strategic management, Pain, Wedbush Securities, Stanford University, Corporate Affairs, Therapy, CNS, A.T. Still University, Horizon Therapeutics, Penn Mutual, Lexicon Pharmaceuticals, Nephrology, Head, Jefferies, Lithium, Biology, Pharmaceutical industry

4M Therapeutics Inc., an early-stage biotechnology company developing treatments for neuropsychiatric and neurodegenerative conditions, today announced the appointment of Kimberly Lee, D.O.

Key Points: 
  • 4M Therapeutics Inc., an early-stage biotechnology company developing treatments for neuropsychiatric and neurodegenerative conditions, today announced the appointment of Kimberly Lee, D.O.
  • as Chief Business Officer and member of the executive management team.
  • “We are excited to welcome Kim to the team to maximize the potential of our pipeline and to drive strategic growth,” said Dr. Pablo Lapuerta, Chief Executive Officer and Co-founder of 4M Therapeutics.
  • Prior to that, she held the role of Chief Corporate Affairs Officer at Taysha Gene Therapies.

Pharmatech Associates Adds Biotech Leader Praveen Tyle, Ph.D. to Board of Trustees

Retrieved on: 
Tuesday, January 16, 2024
Other Health, Professional Services, Pharmaceutical, Oncology, Other Manufacturing, Clinical Trials, Science, Biotechnology, FDA, Health, Consulting, Other Science, Manufacturing, Bausch & Lomb, Trustee, USP, Lexicon Pharmaceuticals

Pharmatech Associates, a subsidiary of the United States Pharmacopeia (USP), today announced it has appointed the biotech expert Dr. Praveen Tyle to its board of trustees.

Key Points: 
  • Pharmatech Associates, a subsidiary of the United States Pharmacopeia (USP), today announced it has appointed the biotech expert Dr. Praveen Tyle to its board of trustees.
  • “As we focus on providing expert consulting services to an array of biotechnology clients, Dr. Tyle’s incomparable experience and valuable market insight will inform the Pharmatech Associates board,” said Emily Kaine, Pharmatech Associates’ board chair.
  • “Dr.
  • “Backed by USP’s sustained investment and global network, Pharmatech has a promising, ambitious long-term global growth trajectory as it helps drug manufacturers meet international regulatory requirements and their own business objectives.”

Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

Retrieved on: 
Thursday, November 30, 2023
T1DM, Food, FDA, AAK1, Type, Lexicon Pharmaceuticals, Patient, Dose-ranging study, Neuropathic pain, Extension, Trial of the century, Diagnosis, PROGRESS, Safety, T2DM, Fast Track, Pharmaceutical industry

THE WOODLANDS, Texas, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has enrolled the first patient in PROGRESS (A Phase 2b, Dose-ranging, Randomized, Double-blind, PlacebO-controlled, Parallel-GRoup, MulticEnter Study with an Open-label Extension in PatientS with Diabetic Peripheral Neuropathic Pain) studying LX9211, a potent, orally-delivered, selective, investigational small molecule inhibitor of adaptor-associated kinase 1 (AAK1).

Key Points: 
  • PROGRESS will enroll adult patients with a diagnosis of type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) with moderate to severe DPNP.
  • The primary endpoint of PROGRESS is a reduction of Average Daily Pain Score (ADPS), consistent with the primary endpoint achieved in the successful RELIEF-DPN-1 Phase 2a proof-of-concept study and, informed by regulatory feedback, the primary endpoint planned for Phase 3 studies of LX9211 in DPNP.
  • The placebo-controlled treatment period of PROGRESS is intended to identify the optimal dosing for Phase 3 studies.
  • The open-label extension is expected to run in parallel with planned next-stage Phase 3 studies, supporting long-term safety requirements for regulatory approval.

Data on Early Clinical Benefit for INPEFA® (Sotagliflozin) Will Be Among Five Lexicon-Sponsored Presentations at the American Heart Association Scientific Sessions 2023

Retrieved on: 
Thursday, November 2, 2023
MA, Food, SGLT, Lexicon Pharmaceuticals, FACC, American Heart Association, Regulation of tobacco by the U.S. Food and Drug Administration, Sotagliflozin, Risk, Hospital, Pennsylvania Convention Center, Patient, Heart failure, MedStar Washington Hospital Center, Data science, Pharmaceutical industry, Research, Brigham

THE WOODLANDS, Texas, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that five data presentations related to INPEFA® (sotagliflozin) will be delivered during the American Heart Association Scientific Sessions 2023, November 11-13, 2023, at the Pennsylvania Convention Center in Philadelphia, PA.

Key Points: 
  • “Our significant upcoming presence at the American Heart Association Scientific Sessions 2023 reflects the dedication of investigators to expanding the scientific evidence available to clinicians and payers as they make decisions around how to best utilize available treatment options in patients,” said Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer.
  • “We look forward to engaging with attendees and continuing to demonstrate both the clinical and economic value of INPEFA.”
    Details of the presentations are as follows:
    Sotagliflozin is associated with early clinical benefit for heart failure and atherosclerotic events – an oral presentation, Sunday, November 12, 2:10 - 2:15 p.m.
  • ET, Board #2122, presented by Slaven Sikirica, M.Sc., Lexicon Pharmaceuticals
    Sotagliflozin, a dual SGLT 1 and 2 Inhibitor, has high membrane affinity and hydrocarbon core location compared with empagliflozin – an ePoster, Sunday, November 12, 3:30 - 3:45 p.m.
  • ET, Board #2222, presented by Preston Mason, M.D., Brigham and Women’s Hospital, Boston, MA
    Relationship between left ventricular ejection fraction and ICD-10 codes among patients hospitalized with heart failure – a poster presentation, Saturday, November 11, 3:00 - 4:15 p.m.

INPEFA® (Sotagliflozin) Receives Coverage From Express Scripts on Its Basic and High Performance Formularies for Commercially Insured Patients

Retrieved on: 
Wednesday, November 1, 2023
FDA, The Guardian Life Insurance Company of America, Food, Medicare, High-performance Integrated Virtual Environment, PBM, Lexicon Pharmaceuticals, Express Scripts, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Chronic kidney disease, Type, Risk, Hospital, Patient, Heart failure, Health insurance, Dietary supplement

THE WOODLANDS, Texas, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Express Scripts, the pharmacy benefits management (PBM) business of The Cigna Group's Evernorth, has determined that it will place INPEFA on its Basic and High Performance formularies for commercially insured patients as of today, November 1, 2023, and in addition to the previously reported Premier Access and Premier Performance national formularies for Medicare patients. These formulary placements will provide access to INPEFA for Express Scripts commercial and Medicare patients in plans that utilize these formularies and who meet the parameters of INPEFA’s FDA-approved indication.

Key Points: 
  • As previously reported, Express Scripts has also determined that it will list INPEFA as a preferred product on Medicare national formularies starting today, November 1, 2023
    THE WOODLANDS, Texas, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Express Scripts, the pharmacy benefits management (PBM) business of The Cigna Group's Evernorth, has determined that it will place INPEFA on its Basic and High Performance formularies for commercially insured patients as of today, November 1, 2023, and in addition to the previously reported Premier Access and Premier Performance national formularies for Medicare patients.
  • These formulary placements will provide access to INPEFA for Express Scripts commercial and Medicare patients in plans that utilize these formularies and who meet the parameters of INPEFA’s FDA-approved indication.
  • “We continue to make progress in establishing access and reimbursement for INPEFA and are pleased by the Express Scripts decision announced today,” said Lonnel Coats, Lexicon’s chief executive officer.
  • INPEFA is currently commercially available in the U.S.

INPEFA® (Sotagliflozin) Receives Preferred Formulary Status With Express Scripts For Medicare Patients

Retrieved on: 
Monday, October 9, 2023
Food, Hope, Type, Express, Express Scripts, PBM, Risk, Hospital, FDA, Medicare, Heart failure, Chronic kidney disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Lexicon Pharmaceuticals, Patient, The Guardian Life Insurance Company of America, Pharmaceutical industry, Dietary supplement

THE WOODLANDS, Texas, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Express Scripts, the pharmacy benefits management (PBM) business of The Cigna Group's Evernorth, has determined that it will place INPEFA on its Premier Access and Premier Performance national formularies for Medicare patients on November 1, 2023. This placement will provide access to INPEFA for Express Scripts Medicare patients in plans that utilize these formularies and who meet the parameters of INPEFA’s FDA-approved indication.

Key Points: 
  • Express Scripts has determined that it will list INPEFA as a preferred product on Medicare national formularies on November 1, 2023
    THE WOODLANDS, Texas, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Express Scripts, the pharmacy benefits management (PBM) business of The Cigna Group's Evernorth, has determined that it will place INPEFA on its Premier Access and Premier Performance national formularies for Medicare patients on November 1, 2023.
  • This placement will provide access to INPEFA for Express Scripts Medicare patients in plans that utilize these formularies and who meet the parameters of INPEFA’s FDA-approved indication.
  • “We are proud to announce this significant milestone for INPEFA and are appreciative of the expeditious steps Express Scripts has taken to make INPEFA available to patients who need it the most,” said Lonnel Coats, Lexicon’s chief executive officer.
  • INPEFA is currently commercially available in the U.S.

Lexicon to Present Post Hoc Analysis of Scored Clinical Trial at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023

Retrieved on: 
Thursday, September 28, 2023
Risk, Heart failure, Hospital, Clinical trial, Doctor of Philosophy, Heart Failure Society of America, Huntington Convention Center of Cleveland, Patient, Lexicon Pharmaceuticals, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Post hoc, Food, Hypertension, Pharmaceutical industry

THE WOODLANDS, Texas, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that a new analysis of clinical trial data for INPEFA® (sotagliflozin) will be presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting, October 6-9, 2023 in Cleveland, Ohio.

Key Points: 
  • SCORED was one of two randomized, double-blind, placebo-controlled Phase 3 cardiovascular outcomes studies that led to FDA approval
    THE WOODLANDS, Texas, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that a new analysis of clinical trial data for INPEFA® (sotagliflozin) will be presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting, October 6-9, 2023 in Cleveland, Ohio.
  • Details of the presentation are as follows:
    Sotagliflozin Reduces The Risk Of Cardiovascular Events In Patients With Left Ventricular Hypertrophy Without Hypertension: A Post Hoc Analysis From SCORED – an ePoster presentation, Sunday, October 8, 8:00 - 8:30 a.m.
  • ET, Viewing Session VI, Huntington Convention Center, presented by Michael J. Davies, PhD, executive director of clinical development, Lexicon Pharmaceuticals.
  • On May 26, 2023, the U.S. Food and Drug Administration approved INPEFA, a once-daily oral tablet, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with:

Lexicon to Present Study Results Relating to Sotagliflozin and LX9211 at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD)

Retrieved on: 
Tuesday, September 26, 2023
University, Heart failure, University of Michigan, Chronic kidney disease, Hospital, T1D, HF, Fast Track, University of California, Doctor of Philosophy, EASD, Patient, Risk, CEST, Internal medicine, Type, Lexicon Pharmaceuticals, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Lexicon, Pharmaceutical industry, Dietary supplement, MD, Diabetes

THE WOODLANDS, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced several upcoming Lexicon-supported data presentations related to heart failure (HF), type 1 diabetes (T1D), and diabetic peripheral neuropathic pain (DPNP). The oral presentations will be made at the 59th Annual Meeting of EASD, October 2-6, 2023, in Hamburg, Germany and online.

Key Points: 
  • The oral presentations will be made at the 59th Annual Meeting of EASD, October 2-6, 2023, in Hamburg, Germany and online.
  • Lexicon is preparing to advance LX9211 into late-stage development in a clinical program directed towards an application for regulatory approval in DPNP.
  • The first late-stage study will be a Phase 2b dose optimization study, with study planning underway and initiation of dosing expected before the end of 2023.
  • “These presentations at EASD will help generate greater awareness of these programs and their potential to help patients across various therapeutic areas.”

Lexicon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 3, 2023
Diabetes, Investment, Trial of the century, Marketing, Life expectancy, Division, Patient, Risk, Research and development, R, American Diabetes Association, University, Heart failure, University of Michigan, Pharmacoeconomics, Randomness, Hospital, FDA, Chronic kidney disease, Efficacy, ID, Administration, AAK1, Webcast, Type, Research, Lexicon, User experience, MI, SG, Metabolism, ISPOR, LVEF, Harvard Medical School, Internal medicine, Heart, Lexicon Pharmaceuticals, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, International Society, Food, Pharmaceutical industry, Cryptocurrency, Dietary supplement, Heart failure with preserved ejection fraction, Endocrinology

THE WOODLANDS, Texas, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended June 30, 2023 and provided an update on key corporate milestones.

Key Points: 
  • “This was a an important and productive quarter for Lexicon with achievement of a transformational milestone for the company and important advancements in our business,” said Lonnel Coats, Lexicon’s chief executive officer.
  • The first late-stage study will be a Phase 2b dose optimization study, with start-up scheduled in the third quarter of 2023 and the initiation of dosing expected in the fourth quarter.
  • For the second quarters of 2023 and 2022, net loss included non-cash, stock-based compensation expense of $3.8 million and $2.8 million, respectively.
  • Lexicon management will hold a live conference call and webcast today at 5:00 pm ET / 4:00 pm CT to review its financial and operating results and to provide a general business update.

Abilita Bio Changes Name to Abilita Therapeutics and Appoints Joel Edwards as Chief Business Officer

Retrieved on: 
Thursday, June 1, 2023
SMA, Partnership, Therapy, Biogen, Colorado State University, Bausch Health, Ball State University, Ionis, Ball, Patient, SAN, Lexicon Pharmaceuticals, Ionis Pharmaceuticals, Pharmaceutical industry, Psychology

SAN DIEGO, June 1, 2023 /PRNewswire/ -- Abilita Bio, a leader in enabling the discovery of membrane protein-targeted therapeutics, announced today the company changed its name to Abilita Therapeutics. The name change reflects the company's new focus on both discovery and early preclinical development. The company also expanded its mission to generate first- and best-in-class therapeutics for development and commercialization through partnerships. The company has four active antibody programs, highlighting the power of Abilita Therapeutics' EMP™ platform. Abilita Therapeutics' expanded focus uniquely positions the company to build value in historically challenging membrane protein targets, making previously undruggable targets druggable.

Key Points: 
  • SAN DIEGO, June 1, 2023 /PRNewswire/ -- Abilita Bio, a leader in enabling the discovery of membrane protein-targeted therapeutics, announced today the company changed its name to Abilita Therapeutics.
  • Aligned with the company's expanded mission, Abilita Therapeutics announced the appointment of Joel Edwards as chief business officer, effective June 1, 2023.
  • He will serve as a member of Abilita Therapeutic's executive leadership team and report to Mauro Mileni, Ph.D., Abilita Therapeutic's chief executive officer.
  • Mr. Edwards will lead Abilita Therapeutics' corporate strategy and business development efforts to maximize the value of the company's EMP™ discovery platform and pipeline through strategic partnerships.